 Adicet Bio today announced that the FDA has granted fast-track designation to its potential treatment for a certain type of cancer. ADI-270 is intended to treat patients with metastatic advanced clear cell renal cell carcinoma. According to the Federal Trade Commission, consumers lost over a billion dollars to romance scams in 2023. Erin Real has more.